Gluten Intolerance Treatment Market to Reach USD 16.18 Billion by 2032 | CAGR 11.8% | Key Players: Takeda, DSM-Firmenich, Enzymedica, Genetic Nutrition, NOW Foods | North America Leads with 40% Share

Market Overview

The Global Gluten Intolerance Treatment Market reached US$ 6.63 billion in 2024 and is projected to reach US$ 16.18 billion by 2032, growing at a CAGR of 11.8% during the forecast period 2024-2032.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/gluten-intolerance-treatment-market?juli

Gluten intolerance, or non-celiac gluten sensitivity, is a condition in which individuals experience symptoms such as bloating, abdominal pain, fatigue, and digestive discomfort after consuming gluten-containing foods, without exhibiting the autoimmune response or intestinal damage characteristic of celiac disease. Although it is a less severe condition, gluten intolerance can still substantially affect an individual's quality of life, leading to dietary restrictions and lifestyle modifications.

The growing prevalence of gluten-related disorders, coupled with heightened consumer awareness of digestive health, is driving demand for targeted treatment options. The market includes a range of products such as dietary supplements, digestive enzyme therapies, probiotics, and emerging pharmaceutical formulations aimed at alleviating symptoms and improving nutrient absorption.

Recent Developments:

✅ January 2026 - United States: Takeda Pharmaceutical Company Limited announced the initiation of Phase II clinical trials for its novel oral enzyme therapy designed to break down immunogenic gluten peptides in the digestive tract, aimed at improving tolerance in gluten-sensitive patients.

✅ November 2025 - United Kingdom: GlaxoSmithKline (GSK) launched a new probiotic supplement line targeting gut microbiome balance in individuals with gluten sensitivity, supporting digestion and reducing bloating.

✅ September 2025 - Germany: BioGaia AB unveiled a gluten-specific probiotic formulation developed to restore intestinal barrier function and reduce gastrointestinal inflammation in gluten-intolerant consumers.

✅ August 2025 - India: Sun Pharmaceutical Industries Ltd. introduced a digestive enzyme capsule designed to enhance gluten breakdown in processed food diets, catering to the rising gluten-free consumer base in Asia-Pacific.

✅ June 2025 - Canada: Viome Life Sciences launched a personalized nutrition platform integrating microbiome analysis with enzyme-based therapies for gluten intolerance management.

✅ April 2025 - Japan: Otsuka Holdings Co., Ltd. announced the development of a peptide-targeting enzyme designed to neutralize gluten peptides before absorption, reducing immune response and intestinal irritation.

✅ February 2025 - Australia: Blackmores Ltd. expanded its gut health portfolio with enzyme-blended dietary supplements aimed at individuals with mild to moderate gluten intolerance.

Mergers & Acquisitions:

✅ January 2026 - United States: AbbVie Inc. acquired a biotechnology startup specializing in enzyme-based gluten degradation technologies to expand its gastrointestinal therapeutic segment.

✅ October 2025 - Europe: Nestlé Health Science completed the acquisition of a European nutrition firm focused on gluten-free supplements and probiotic-based digestive support products.

✅ August 2025 - India: Dr. Reddy's Laboratories acquired a nutraceutical company developing gluten intolerance management supplements, strengthening its consumer health portfolio.

✅ July 2025 - Switzerland: Roche Holding AG partnered with a gut health biotech startup to co-develop microbiome-based therapeutics for gluten sensitivity and related digestive disorders.

✅ May 2025 - United States: Amway Corporation launched a strategic collaboration with a U.S.-based enzyme manufacturer to co-develop plant-based digestive enzyme blends for gluten-sensitive consumers.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=gluten-intolerance-treatment-market?Juli

Key Players:

DSM-Firmenich - 14%
Leads the market with a broad portfolio of enzyme-based digestive health products and gluten-degrading formulations, supported by strong R&D in nutritional biosciences and personalized wellness solutions.

Genetic Nutrition - 10%
Focused on precision nutrition and enzyme supplements tailored for gluten and lactose intolerance, leveraging genetic and microbiome-based diagnostics to enhance treatment personalization.

NOW Foods - 9%
Holds a strong position in the nutraceuticals segment, offering gluten support enzyme blends and probiotics that target digestive discomfort, particularly within the North American market.

Enzymedica - 11%
A major player in enzyme therapy, Enzymedica's "GlutenEase" and related digestive health products have achieved strong consumer adoption for non-celiac gluten sensitivity management.

AMYRA Biotech AG - 8%
Specializes in biotechnological enzyme development targeting gluten and other peptide-based intolerances, with ongoing clinical programs for next-generation oral enzyme therapeutics.

KLAIRE LABS - 7%
Recognized for high-quality probiotics and enzyme supplements supporting gut health, with a growing presence in the gluten sensitivity and microbiome wellness market.

Precigen - 10%
Focuses on developing genetically engineered enzyme-based therapeutics for metabolic and digestive disorders, with active programs targeting gluten peptide degradation.

Takeda Pharmaceutical Company - 15%
Leads the pharmaceutical segment with advanced clinical-stage enzyme therapies and research in gut immune modulation, reinforcing its leadership in gastrointestinal therapeutics.

Market Segmentation:

By Treatment Type: Dietary management dominates the market with a 40% share, as gluten-free diets remain the cornerstone of managing gluten intolerance. Pharmaceuticals hold a 25% share, driven by enzyme-based therapies and emerging drug candidates targeting non-celiac gluten sensitivity. Nutritional supplements account for 20%, supported by enzyme blends, probiotics, and gut-health products aimed at symptom relief. The remaining 15% comprises other treatments, including complementary and alternative therapies such as herbal formulations and specialized functional foods.

By Patient Type: Adults constitute the largest segment with a 60% share, reflecting higher diagnosis rates and lifestyle-driven adoption of supportive therapies. Pediatric patients account for 25%, as early-onset gluten intolerance cases gain recognition and require age-appropriate management. Geriatric patients represent 15%, with demand driven by digestive health concerns and increased prevalence of gluten sensitivity in older populations.

By Formulation: Tablets lead with a 45% share, favored for ease of use and standardized dosing of enzyme supplements and pharmaceuticals. Powders account for 30%, commonly used in nutritional supplements and meal replacements designed for gluten-free diets. Liquids make up the remaining 25%, including oral enzyme solutions, liquid probiotics, and specialized formulations for pediatric or elderly patients.

By Distribution Channel: Online pharmacies dominate with a 35% share, reflecting growing consumer preference for convenient home delivery and discreet purchase of gluten-intolerance products. Retail pharmacies hold 30%, supported by pharmacist recommendations and in-store visibility. E-commerce platforms, including large marketplaces and direct-to-consumer brand websites, account for 35%, highlighting the strong digital adoption for niche health products.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/gluten-intolerance-treatment-market?Juli

Regional Insights:

North America holds the largest share in the global gluten intolerance treatment market, accounting for approximately 40% of revenue. The dominance is driven by high awareness of gluten-related disorders, widespread adoption of gluten-free diets, and strong healthcare infrastructure supporting diagnostics and treatment. The United States, in particular, has seen a surge in demand for enzyme therapies, nutritional supplements, and gluten-free dietary products, with retailers and e-commerce platforms offering extensive product portfolios.

Europe follows closely with a 30% market share, fueled by increasing prevalence of gluten sensitivity and celiac disease, supportive regulatory frameworks for gluten-free labeling, and strong consumer preference for functional foods and nutraceuticals. Countries such as Germany, the UK, and Italy are witnessing significant adoption of enzyme therapies and nutritional supplements to manage gluten intolerance symptoms.

Asia-Pacific represents around 20% of the market and is emerging rapidly due to rising awareness of digestive health, growing disposable incomes, and expanding e-commerce channels. Markets like Japan, China, and India are seeing increasing penetration of dietary management products and enzyme-based therapies, with multinational and local brands actively expanding distribution networks.

Rest of the World (RoW) accounts for the remaining 10%, with growth driven by Latin America and the Middle East, where increasing urbanization, changing dietary patterns, and rising healthcare access are encouraging adoption of gluten intolerance treatments. Although awareness is lower compared to North America and Europe, education campaigns and online retail expansion are creating new opportunities in these regions.

Market Dynamics:

Driver:
The rising prevalence and awareness of gluten intolerance and celiac disease are expected to significantly drive the market for gluten intolerance treatments. Improved diagnostic techniques and increased screening by healthcare providers are resulting in a larger patient population being accurately identified. As more individuals receive diagnoses, demand for targeted therapies such as enzyme supplements, nutritional interventions, and emerging pharmaceutical options continues to grow.

Patients increasingly seek solutions beyond strict gluten-free diets, including supportive treatments that aid digestion and alleviate symptoms. This trend is further amplified by educational initiatives and awareness campaigns, which encourage patients to explore comprehensive management approaches, thereby expanding market potential.

Restraint:
The gluten intolerance treatment market faces constraints due to the widespread reliance on non-medical management strategies. A gluten-free diet remains the primary and most effective method for controlling symptoms, leading many individuals to forego pharmaceutical or supplement-based treatments.

Additionally, the perception that lifestyle modifications and dietary adherence are sufficient to manage symptoms reduces the urgency for alternative therapies. This patient behavior limits the adoption of medical interventions, thereby restraining market growth despite increasing diagnosis rates and awareness.

Resistance development also exacerbates crop yield losses. According to the CABI report, an estimated 20-40% of global crop yields are lost annually due to pests and diseases, with bacterial infections accounting for a significant portion. While this underscores the ongoing need for effective bactericides, it also highlights the urgency for innovation in resistance management through product rotation, bio-based alternatives, and integrated disease management strategies.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.